ClinicalTrials.gg
Active, not recruitingNCT06563726SALTUpdated Nov 18, 2026

Sodium Awareness in Lactation Trial

An interventional study of point-of-care milk sodium testing in Breastfeeding, Preterm Birth and Breast Pumping, sponsored by The Hospital for Sick Children. Active, not recruiting at 2 sites in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-18.

Primary conditionBreast Milk ExpressionRegistry: Breast FeedingReclassifiedWhy we changed it
Registry
Breast Feeding — the first condition term the registry derived for this study.
ClinicalTrials.gg
Breast Milk Expression
Why
  1. The study's listed conditions name Breast Milk Expression, a narrower term within Breast Feeding.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The Hospital for Sick Children · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 18, 2026Now Active, not recruitingPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 32 studies in Breast Milk Expression with a site in United States — 6 open to participants now, 10 under way, none of them phase 3. Breast Milk Expression · United States.

Planned enrollment
15th of 22
40 · median 52
Started
2025
with 4 others
No phase
21 of 32
4 open now
Registered
27th of 32
by date

Among the 32 studies in Breast Milk Expression with a site in United States, this one is the 15th largest by planned enrollment of the 22 interventional ones that give a count, is one of 5 that started in 2025, is one of 21 with no phase, and was the 27th registered.

Breast Milk Expression

88 studies on the registry are indexed under Breast Milk Expression; 19 are open to participants now.

Browse Breast Milk Expression studies →

Open to participants now

6 of the 32 studies in Breast Milk Expression with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Breast Milk Expression studies recruiting now, 6 (46%) set no upper age limit and 7 (54%) stop at 75 or younger; 3 take children under 18; 10 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Breast Milk Expression with a site in United States, or all of them as a file.
02

Study summary

SALT is a multi-centre, non-blinded, non-randomized prospective interventional pilot study teaching lactating parents of hospitalized preterm infants how to test their breastmilk sodium (Na) using point-of-care (POC) meters. A drop in Na is a sign of secretory activation in the breast that is associated with adequate short and long-term breast milk volumes in this vulnerable population.

Primary Objective: Establish feasibility, acceptance, and time cost of parent-led parent milk Na testing in the first 14 days postpartum

Secondary Objective: Further investigate relationships between pumping behaviours, lactation risk factors, daily milk Na and lactation outcomes

Exploratory Objective: Explore how POC Na data may be used to modify pumping behaviour and milk volumes

03

Conditions studied

  • Breastfeeding
  • Preterm Birth
  • Breast Pumping
  • Lactation; Insufficient, Partial

Browse trials for

04

In context

Breast Milk Expression Reclassified

88 studies on the registry are indexed under Breast Milk Expression; 19 are open to participants now.

This study's planned enrollment of 40 is below the median of 60 across 49 interventional studies indexed under Breast Milk Expression.

Browse Breast Milk Expression studies →

Lead sponsor

The Hospital for Sick Children is the lead sponsor of 579 studies on the registry; 81 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 1 (14%) have results posted.

Compared within Breast Milk Expression, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Feeding. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Consent provided
  2. Have delivered a preterm singleton or twin infant at \<35 weeks gestation admitted to a study NICU at birth or transferred into a study NICU from another NICU within the first 72 hours postpartum
  3. Day 5 or less postpartum (Day 1 = day of delivery) upon enrollment (ideally day 3 or less)
  4. Plans to lactate at least 2 weeks and initiate lactation with a breast pump
  5. Expected infant NICU stay of 7+ (ideally 14+) days in enrollment NICU(s)

Exclusion criteria

Exclusion Criteria:

  1. Potential study participant's infant is critically ill and not expected to survive or has lethal diagnosis with plans by medical team/family to redirect care
  2. Has delivered triplets or higher order multiples (potential confounder for lactation challenges; of note, triplets or higher are rare, on the order of a few parents annually)
  3. Lactation (s) (i.e., active chemotherapy) or declines lactation initiation
  4. History of breast surgery that may affect ability to lactate (i.e., breast reduction; breast augmentation that utilized nipple incisions)
  5. Using or planning to use hormonal in the first 14 days post-partum as may affect secretory activation/lactation
  6. Unable/unwilling to be present in study NICU during any of first 5 days postpartum
  7. Presumption by the medical team that infant will be in study NICU for \<5 days
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

06

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Interventions

  • Diagnostic testpoint-of-care milk sodium testing

    Data-driven interventions to improve early lactation success are lacking, and parents who deliver preterm are at high risk of lactation challenges. We will be studying feasibility, acceptability, and time cost of teaching lactating parents of hospitalized preterm infants how to test their breastmilk sodium (Na) using point-of-care (POC) meters. As a secondary aim, we will assess the potential to use these POC sodium results to guide personalized lactation care in the form of altered pumping schedules in an attempt to reduce breastmilk Na. A drop in Na is a sign of secretory activation in the breast that is associated with adequate short and long-term breast milk volumes in this vulnerable population.

07

What researchers measure

Primary outcomes

  1. Establish feasibility of parent-led longitudinal parent milk Na testing in the first 14 days postpartum: economic

    We will collect time cost of milk testing, including teaching parents how to test milk and daily time testing milk. This outcome will include time (in hours) spent in the first 14 days for parent and staff, with a health economist determining costs for that time

    Time frame: First 14 days postpartum

  2. Establish feasibility of parent-led longitudinal parent milk Na testing in the first 14 days postpartum: parent acceptance via interviews

    We will collect qualitative data on parent acceptance and feelings about Na testing from parent interviews

    Time frame: First 14 days postpartum

  3. Establish feasibility of parent-led longitudinal parent milk Na testing in the first 14 days postpartum: parent acceptance via surveys

    We will collect qualitative data on parent acceptance and feelings about Na testing from parent surveys

    Time frame: First 14 days postpartum

Secondary outcomes

  1. Investigate inter-relationships between pumping frequency, parent lactation risk factors, daily milk Na levels and longer term lactation outcomes (milk provision at NICU discharge).

    We will assess interrelationships between aforementioned factors and milk provision at NICU discharge (exclusive, any, none). Note these are not necessarily correlations, but relationships and associations that we will analyze and explore in various models and combinations, so these outcome cannot be separated.

    Time frame: Enrollment to infant NICU discharge, up to 52 weeks (average NICU stay is about 10 weeks)

  2. Investigate inter-relationships between pumping frequency, parent lactation risk factors, daily milk Na and short term lactation outcomes (coming to volume)

    We will assess interrelationships between aforementioned factors and coming to volume (pumping at least 500mL/day by postpartum day 14).Note these are not necessarily correlations, but relationships and associations that we will analyze and explore in various models and combinations, so these outcomes cannot be separated.

    Time frame: First 14 days postpartum

Other outcomes

  1. Explore if POC Na data used to recommend changes in pumping behaviour is associated with actual changes in parent pumping behaviour

    Explore in parents whom we recommend to modify pumping frequency, rates of coming to volume by day 14 (pumping at least 500mL/day)

    Time frame: First 14 days postpartum

  2. Explore how POC Na data used to recommend changes in pumping behaviour is associated with short-term milk volumes

    Determine in parents whom we recommend to modify pumping frequency based on POC Na, how often they actually followed our recommendations

    Time frame: First 14 days postpartum

08

Study locations

2 sites
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2025 to primary completion in Jan 2026, 9 months.

Of 32 non-industry interventional studies with no phase under Breast Milk Expression, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's 9 months is below that.

Counting every sponsor, half of 39 studies reached it within 12 months; a quarter within 5 and three quarters within 28.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Dec 2025 → Jan 2026 and completion Mar 2026 → Mar 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2024
First posted
Aug 21, 2024
StartActual
Mar 10, 2025
Primary completionActual
Jan 3, 2026was Dec 2025
CompletionEst.
Mar 2027was Mar 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 18, 2026
Primary completion
Dec 2025→Jan 3, 2026 (actual)
Nov 18, 2026
Study completion
Mar 2026→Mar 2027
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    Recruiting→Active, not recruiting
    Primary completion Dec 2025→Jan 3, 2026 (now actual)
    Study completion Mar 2026→Mar 2027
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT06563726
Responsible party
Samantha Anthony (Health Clinician Scientist, Associate Professor, The Hospital for Sick Children) — Principal investigator
First posted
Aug 21, 2024
Start date
Mar 10, 2025
Primary completion
Jan 3, 2026
Completion
Mar 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Samantha J. Anthony, PhD
principal investigator · The Hospital for Sick Children

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion